Daewoong unveils new Indonesian stem cell facility with GMP certification
South Korean drug maker Daewoong Pharmaceutical has announced the launch of a new stem cell plant in Indonesia, marking the 20th anniversary of its entry into the Indonesian market. The facility is set to drive large-scale research and development projects in collaboration with local pharmaceutical and biotech industries, according to the firm. The stem cell plant, established by Daewoong Biologics Indonesia -- a subsidiary of Daewoong Pharmaceutical -- will begin full-scale operations following
Sept. 13, 2024